Immuno-Oncology
Specialty Channel

Featured Article
The President of ESMO discusses what attendees of the annual ESMO World Congress on GI Cancer can expect from the virtual 2020 event.
At the virtual COA 2020 Conference, Dr Grothey discussed the role of gut microbiome in cancer treatment response.
A computed tomography radiomics signature is able to predict response to immune checkpoint inhibitors at baseline for patients with solid tumors.
In patients with advanced solid tumors, therapy with pamiparib plus tislelizumab was well-tolerated and demonstrated clinical benefit.
A recent study suggests the use of integrated tumor microenvironment-based biomarkers to predict responses to immunotherapy in patients with advanced NSCLC.
True or false: In a recent study, immune checkpoint inhibitor treatment was found to be associated with fatal toxic effects in patients with cancer.
A higher tumor mutational burden is associated with improved survival after immunotherapy across a wide variety of cancer types, researchers report.
Immune checkpoint inhibitor treatment can be associated with fatal toxic effects, according to a systematic review and meta-analysis.
The magnitude of benefit of immune checkpoint inhibitors on overall survival for patients with advanced cancers is sex-dependent.

News

In a presentation at the virtual COA 2020 Conference, Dr Jain discussed the rationale for combining stereotactic RT with immunotherapy in patients with metastatic cancer.
At the virtual COA 2020 Conference, Dr Grothey discussed the role of gut microbiome in cancer treatment response.
A computed tomography radiomics signature is able to predict response to immune checkpoint inhibitors at baseline for patients with solid tumors.
In patients with advanced solid tumors, therapy with pamiparib plus tislelizumab was well-tolerated and demonstrated clinical benefit.

Interactive Features

True or false: In a recent study, immune checkpoint inhibitor treatment was found to be associated with fatal toxic effects in patients with cancer.
Stay in the know.
OncNet Newsletter